ASP 3652

Drug Profile

ASP 3652

Alternative Names: ASP-3652

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action Afferent neuron inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Interstitial cystitis; Prostatitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 31 Oct 2014 Discontinued - Phase-I for Interstitial cystitis in Japan (PO)
  • 31 Oct 2014 Discontinued - Phase-II for Interstitial cystitis in Belgium, Czech Republic, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia and Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top